Description
Innovative technology, powerful insights.
Comprehensive, novel technology in our RESONATE CRT-Ds helps physicians to identify heart failure early, restore chronotrophic competence, and improve CRT response in most patients. And they are fueled by the longest-lasting battery technology available, substantially reducing major complications and costs associated with battery replacement.1
In addition, comprehensive shock features to prevent sudden cardiac death are available today and for the future.
Product Details
Identify heart failure decompensation, increase CRT response, reduce costs, and improve quality of life in heart failure patients with our RESONATE family of implantable CRT-Ds (cardiac resynchronization therapy defibrillators).
Boston Scientific devices are unique by providing 8 shocks in the VF zone, the option to choose shock polarity, and automatically invert shock polarity in a series of shocks
HeartLogic™ Heart Failure Diagnostic can predict heart failure events weeks in advance with minimal alerts2
SmartCRT™ Technology provides customized programming to obtain CRT response in most patients3
EnduraLife™ Battery Technology extends device longevity (up to 13.2 years even with MultiSite Pacing turned on)*
RightRate™ Minute Ventilation is the only sensor clinically proven to restore chronotropic competence4 (available only in RESONATE HF)
Clinical Data
MANAGE-HF trial
Investigated the clinical integration and safety of the FDA-approved HeartLogicTM Heart Failure Diagnostic in the management of patients with heart failure9:
HeartLogic was safely integrated into clinical care
Early treatment augmentation was associated with more rapid recovery of the HeartLogic index compared to patients with no change in treatment following an alert
67% reduction in heart failure hospitalizations compared to pre-study9
Read the MANAGE-HF clinical trial summary
SMART-MSP trial
The SMART-MSP clinical trial exceeded both its end points:
Safety Endpoint: The MultiSite Pacing (MSP) feature-related complication-free rate at 180 days post MSP on is 99%
Effectiveness Endpoint: 51% of the non-responders at 6 months converted to responders at 12 months3
Read the SMART-MSP clinical trial summary
NAVIGATE X4 trial
The NAVIGATE X4 trial was a prospective, non-randomized, multi-center, single-arm, clinical study. With 764 patients in 88 implant centers.
50% of ACUITY X4 leads were placed in 6 minutes or less and required no reoperations due to pacing capture or thresholds
77.3% of ACUITY X4 Spiral leads were programmed with a proximal electrode as the pacing cathode5
Read the NAVIGATE X4 clinical trial data
Reviews
There are no reviews yet.